Results 101 to 110 of about 3,220 (195)

Physiologically based pharmacokinetic modeling and simulation of topiramate in populations with renal and hepatic impairment and considerations for drug–drug interactions

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 510-522, March 2025.
Abstract Topiramate (TPM) is a broad‐spectrum antiepileptic drug (AED) commonly prescribed for approved and off‐label uses. Routine monitoring is suggested for clinical usage of TPM in special population due to its broad side effect profile. Therefore, it is crucial to further explore its pharmacokinetic characteristics.
Shuqing Chen, Chaozhuang Shen, Yuchen Tian, Yuhe Peng, Jing Hu, Haitang Xie, Ping Yin   +6 more
wiley   +1 more source

Perspectives for integrating human and environmental risk assessment and synergies with socio-economic analysis [PDF]

, 2013
International audienceFor more than a decade, the integration of human and environmental risk assessment (RA) has become an attractive vision. At the same time, existing European regulations of chemical substances such as REACH (EC Regulation No.
Aicher, Lothar, Andres, Sandrine, Backhaus, T., Brignon, Jean-Marc, Capri, Ettore, Ciffroy, Philippe, Cronin, Mark, Faust, Michael, Frewer, L., Georgiou, S., Marchis, A., Mattas, K., Mombelli, Enrico, Peijnenburg, W., Pery, Alexandre R.R., Schuurmann, Gerrit, Tebby, Cléo, Tissot, Sylvie, Vergnaud, Jean-Christophe, Wilks, Martin   +19 more
core   +4 more sources

Development of a physiologically‐based pharmacokinetic model for Ritonavir characterizing exposure and drug interaction potential at both acute and steady‐state conditions

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 523-539, March 2025.
Abstract Ritonavir (RTV) is a potent CYP3A inhibitor that is widely used as a pharmacokinetic (PK) enhancer to increase exposure to select protease inhibitors. However, as a strong and complex perpetrator of CYP3A interactions, RTV can also enhance the exposure of other co‐administered CYP3A substrates, potentially causing toxicity.
Lien Thi Ngo, Woojin Jung, Tham Thi Bui, Hwi‐yeol Yun, Jung‐woo Chae, Jeremiah D. Momper   +5 more
wiley   +1 more source

Analgosedation in paediatric severe traumatic brain injury (TBI): practice, pitfalls and possibilities [PDF]

, 2017
Analgosedation is a fundamental part of traumatic brain injury (TBI) treatment guidelines, encompassing both first and second tier supportive strategies.
de Lange, E.C.M. (E. C.M.), Hunfeld, M. (Maayke), Ketharanathan, N. (Naomi), Rohlwink, U. (U.), Tibboel, D. (Dick), Wildschut, E.D. (Enno), Yamamoto, Y. (Y.)   +6 more
core   +3 more sources

Disease–Drug–Drug Interaction of Imatinib in COVID‐19 ARDS: A Pooled Population Pharmacokinetic Analysis

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 583-595, March 2025.
ABSTRACT Prior pharmacokinetic (PK) analysis revealed that increased alpha‐1‐acid glycoprotein (AAG) levels are associated with decreased imatinib unbound fraction in coronavirus disease 2019 (COVID‐19) patients. This study aimed to investigate the PK of total and unbound concentrations of imatinib and the metabolite N‐desmethyl imatinib in ...
Medhat M. Said, Job R. Schippers, Leila Atmowihardjo, Yingxue Li, Mick S. van der Plas, Harm J. Bogaard, Lieuwe D. J. Bos, Ron A. A. Mathôt, Jurjan Aman, Eleonora L. Swart, Imke H. Bartelink   +10 more
wiley   +1 more source

Modeling Three-dimensional Invasive Solid Tumor Growth in Heterogeneous Microenvironment under Chemotherapy

, 2018
A systematic understanding of the evolution and growth dynamics of invasive solid tumors in response to different chemotherapy strategies is crucial for the development of individually optimized oncotherapy.
Chen, Guo, Fan, Qihui, Hai, Miaomiao, Hu, Zhijian, Jiao, Yang, Liu, Liyu, Liu, Ruchuan, Shuai, Jianwei, Xie, Hang, Yang, Jiaen, Yang, Yue   +10 more
core   +1 more source

Towards a rational design of solid drug nanoparticles with optimised pharmacological properties. [PDF]

, 2016
Solid drug nanoparticles (SDNs) are a nanotechnology with favourable characteristics to enhance drug delivery and improve the treatment of several diseases, showing benefit for improved oral bioavailability and injectable long-acting medicines.
Alexis, Baert, Bland, Bosgra, Breemen, Chiappetta, Cho, Costa, Crewe, Deschamps, Doh, Fernandez, Haessler, Ittrich, Jia, Joralemon, Kaminskas, Kettler, Klooster, Lee, Li, Liptrott, Lyseng-Williamson, Markowitz, Marrache, Martin, Mathaes, McDonald, McDonald, Moss, Moss, Ogburn, Ohtsuki, Ong, Portenoy, Poulin, Qhattal, Roche, Samtani, Sareen, Schrade, Siccardi, Sikarra, Smith, Spreen, Thakor, Togami, Vrouenraets, Ward, Weir, Wessler, Wu, Xue, Zhang, Zhang   +54 more
core   +1 more source

Transforming Treatment: The Impact of Bariatric Surgery on Oral Drug Absorption

Obesity Reviews, EarlyView.
ABSTRACT Obesity represents a significant threat to global public health, with an estimated 16% of adults worldwide (2022) being classified as people with obesity, with a body mass index of 30 or more. Bariatric surgery is regarded as the most effective treatment option for people with obesity, with the three main types of bariatric surgery being ...
Danielle Wigg, Andrea Edginton, Matthew D. Jones, Nikoletta Fotaki   +3 more
wiley   +1 more source

EURL ECVAM Workshop on New Generation of Physiologically-Based Kinetic Models in Risk Assessment [PDF]

, 2017
The European Union Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM) Strategy Document on Toxicokinetics (TK) outlines strategies to enable prediction of systemic toxicity by applying new approach methodologies (NAM).
Bessems, J, Desalegn, A, Dorne, JL, Gosling, JP, Heringa, MB, Joossens, E, Klaric, M, Kramer, N, Loizou, G, Louisse, J, Lumen, A, Madden, JC, Paini, A, Patterson, EA, Proenca, S, Punt, A, Setzer, RW, Suciu, N, Tan, YM, Troutman, J, Worth, A, Yoon, M   +21 more
core   +2 more sources

Pharmacokinetics of CYP2C19- and CYP3A4-Metabolized Drugs in Cirrhosis Using a Whole-Body PBPK Approach

Pharmaceutics
Background/Objectives: Cirrhosis significantly alters physiological function and drug metabolism, particularly for medications primarily metabolized by CYP2C19 and CYP3A4.
Ruijing Mu, Jingjing Gao, Xiaoli Wang, Jing Ling, Nan Hu, Hanyu Yang   +5 more
doaj   +1 more source